Pharmaceutical Research Details

Pharmaceutical Research

Pharmaceutical science bridges chemistry, biology, and clinical science to develop safe and effective therapeutic agents.

Drug discovery is one of the most capital-intensive scientific endeavors in existence — averaging over $2 billion and 12 years to bring a single drug to market. Failure rates remain stubbornly high: approximately 90 percent of drugs fail between preclinical testing and FDA approval. Artificial intelligence is compressing both timelines and costs by orders of magnitude. In early 2026, GSK committed $50 million upfront to NOETIK for oncology artificial intelligence models, and Eli Lilly paid a mid-eight-figure annual access fee to Chai Discovery for biologics design. These partnerships signal a fundamental shift: major pharmaceutical companies are now outsourcing artificial intelligence-driven discovery to specialized firms rather than building capabilities in-house. Biopharma merger and acquisition activity reached $84 billion in the first quarter of 2026 alone — the strongest start to a year since 2019. If the pace holds, total 2026 deal value could exceed $250 billion, second only to 2019's record.

Key research areas in pharmaceutical discovery include messenger RNA therapeutics beyond infectious diseases, antibody-drug conjugates (ADCs) for cancer, oral GLP-1 agonists for metabolic disease, artificial intelligence-designed small molecules, and adaptive clinical trial design that uses interim data to redirect trials toward more promising patient populations. The market for artificial intelligence in pharma is estimated at $1.94 billion in 2025 and forecasted to reach $16.49 billion by 2034, accelerating at a compound annual growth rate of 27 percent.

Generative artificial intelligence is increasingly used to design novel drug candidates with optimized properties. Insilico Medicine offers an end-to-end artificial intelligence drug discovery platform from target identification to molecule generation and clinical trial design, with an artificial intelligence-designed drug already advancing through Phase II trials — visit insilico.com. Atomwise uses its AtomNet deep learning platform to screen billions of compounds against disease targets, with over 250 active research institution collaborations across oncology, neurology, and infectious disease — visit atomwise.com. Schrödinger provides physics-based computational tools for drug discovery integrated with machine learning, enabling rapid and accurate discovery of novel molecules — visit schrodinger.com. BenevolentAI achieved recognition for identifying baricitinib as a COVID-19 therapeutic during the pandemic and continues advancing multiple programs toward the clinic — visit benevolent.ai. Recursion Pharmaceuticals has recently acquired Exscientia and now references partnered portfolios with Sanofi, Merck, Roche, and Bayer, with an end-to-end setup that turns wet-lab biology into a continuous data loop — visit recursion.com. The FDA's Centre for Drug Evaluation and Research publishes drug approval data, clinical trial guidance, and regulatory science updates — visit fda.gov/drugs. For clinical trial tracking globally, ClinicalTrials.gov is the primary public registry listing over 600,000 studies — visit clinicaltrials.gov. BioMed Nexus publishes monthly tracking of the top artificial intelligence drug discovery companies with clinical candidates in development — visit biomednexus.com